3 results
The goal of the fenebrutinib development program in MS is to evaluate the benefits and risks of fenebrutinib treatment across the spectrum of patients with MS. Based on the existing toxicology, pharmacology, and clinical experience with fenebrutinib…
The primary objective for this trial is to assess the local cancer control achieved with FLA in patients with localized low to intermediate risk prostate cancer (Gleason 3+3, 3+4 or Gleason 4+3).Secondary objectives are to determine effectiveness of…
The purpose of the study is to provide efficacy, safety and tolerability data for remibrutinib to support regulatory approval worldwide as a treatment for relapsing multiple sclerosis (RMS). Two identical Phase III trials (CLOU064C12301 and…